Jinsy Andrews, MD. MSc - Columbia University - Director of Neuromuscular Clinical Trials

Jinsy Andrews

MD. MSc

Columbia University

Director of Neuromuscular Clinical Trials

New York, NY | United States

Main Specialties: Neurology

Additional Specialties: Neuromuscular


Top Author

Jinsy Andrews, MD. MSc - Columbia University - Director of Neuromuscular Clinical Trials

Jinsy Andrews

MD. MSc

Introduction

Primary Affiliation: Columbia University - New York, NY , United States

Specialties:

Additional Specialties:

Research Interests:

Education

May 2009
Columbia University
MSc
Biostatistics
May 2001
Albany Medical College
MD
Medicine
May 1994
Union College
BS
Biology

Publications

16Publications

430Reads

2897Profile Views

35PubMed Central Citations

Respiratory measures in amyotrophic lateral sclerosis.

Amyotroph Lateral Scler Frontotemporal Degener 2018 Aug 23;19(5-6):321-330. Epub 2018 Mar 23.

f Eleanor and Lou Gehrig ALS Center, The Neurological Institute, Columbia University , New York , NY , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/21678421.2018.1452945DOI Listing
August 2018
36 Reads
2.591 Impact Factor

Longitudinal modeling to predict vital capacity in amyotrophic lateral sclerosis.

Amyotroph Lateral Scler Frontotemporal Degener 2018 05 20;19(3-4):294-302. Epub 2017 Dec 20.

a Origent Data Sciences, Inc , Vienna , VA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/21678421.2017.1418003DOI Listing
May 2018
30 Reads
2.591 Impact Factor

CK-2127107 amplifies skeletal muscle response to nerve activation in humans.

Muscle Nerve 2018 05 11;57(5):729-734. Epub 2017 Dec 11.

Cytokinetics, Inc., 280 East Grand Avenue, South San Francisco, California, 94080, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mus.26017DOI Listing
May 2018
31 Reads
2 Citations
2.283 Impact Factor

Profile of medical care costs in patients with amyotrophic lateral sclerosis in the Medicare programme and under commercial insurance.

Amyotroph Lateral Scler Frontotemporal Degener 2018 02 11;19(1-2):134-142. Epub 2017 Sep 11.

b Cytokinetics, Inc , South San Francisco , CA , USA , and.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/21678421.2017.1
Publisher Site
http://dx.doi.org/10.1080/21678421.2017.1363242DOI Listing
February 2018
44 Reads
2.591 Impact Factor

A randomized, placebo-controlled, double-blind phase IIb trial evaluating the safety and efficacy of tirasemtiv in patients with amyotrophic lateral sclerosis.

Amyotroph Lateral Scler Frontotemporal Degener 2016 Jul-Aug;17(5-6):426-35. Epub 2016 Mar 16.

b Cytokinetics, Inc. , South San Francisco , California , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/21678421.2016.1148169DOI Listing
October 2017
29 Reads
5 Citations
2.591 Impact Factor

Primary Lateral Sclerosis and Early Upper Motor Neuron Disease: Characteristics of a Cross-Sectional Population.

J Clin Neuromuscul Dis. 2016 Mar;17(3):99-105.

Journal of Clinical Neuromuscular Disease

OBJECTIVE: The goals of this study were to characterize clinical and electrophysiologic findings of subjects with upper motor neuron disease and to explore feasibility of clinical trials in this population. METHODS: Twenty northeast amyotrophic lateral sclerosis consortium (northeast amyotrophic lateral sclerosis) sites performed chart reviews to identify active clinical pure upper motor neuron disease patients. Patients with hereditary spastic paraplegia or meeting revised El Escorial electrodiagnostic criteria for amyotrophic lateral sclerosis were excluded. Patients were classified into 2 groups according to the presence or absence of minor electromyography (EMG) abnormalities. RESULTS: Two hundred thirty-three subjects with upper motor neuron disease were identified; 217 had available EMG data. Normal EMGs were seen in 140 subjects, and 77 had minor denervation. Mean disease duration was 84 (±80) months for the entire cohort with no difference seen between the 2 groups. No difference was seen in clinical symptoms, disability, or outcome measures between the 2 groups after correcting for multiple comparisons. CONCLUSIONS: Minor EMG abnormalities were not associated with phenotypic differences in a clinical upper motor neuron disease population. These findings suggest that subtle EMG abnormalities can not necessarily be used as a prognostic tool in patients with clinical upper motor neuron disease. This study also demonstrates the availability of a large number of patients with upper motor neuron diseases within the northeast amyotrophic lateral sclerosis network and suggests feasibility for conducting clinical trials in this population.

View Article
March 2016
22 Reads

Disease burden in upper motor neuron syndromes: a survey of patient perspectives.

J Clin Neuromuscul Dis. 2014 Dec;16(2):104-5

J Clin Neuromuscul Dis.

View Article
December 2014
24 Reads

Body mass index (BMI) as predictor of ALSFRS-R score decline in ALS patients.

Amyotroph Lateral Scler Frontotemporal Degener 2013 Apr 1;14(3):212-6. Epub 2013 Mar 1.

Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/21678421.2013.770028DOI Listing
April 2013
50 Reads
7 Citations
2.591 Impact Factor

Experience with the Awaji Island modifications to the ALS diagnostic criteria.

Muscle Nerve 2010 Nov;42(5):831-2

Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mus.21841DOI Listing
November 2010
22 Reads
1 Citation
2.283 Impact Factor

Study of 962 patients indicates progressive muscular atrophy is a form of ALS.

Neurology. 2009 Nov 17;73(20):1686-92.

Neurology

BACKGROUND: Progressive muscular atrophy (PMA) is clinically characterized by signs of lower motor neuron dysfunction and may evolve into amyotrophic lateral sclerosis (ALS). Whether PMA is actually a form of ALS has important consequences clinically and for therapeutic trials. We compared the survival of patients with PMA or ALS to analyze the clinical features that influence survival in PMA. METHODS: We reviewed the medical records of patients with PMA (n = 91) or ALS (n = 871) from our ALS Center and verified survival by telephoning the families or using the National Death Index. RESULTS: In PMA, patients were more likely to be male (p < 0.001), older (p = 0.007), and lived longer (p = 0.01) than in ALS. Cox model analysis suggested that the risk of death increased with age at onset in both patient groups (p < 0.005). Upper motor neuron (UMN) signs developed in 22% of patients with PMA within 61 months after diagnosis. Demographic and other clinical variables did not differ at diagnosis between those who did or did not develop UMN signs. In PMA, the factors present at diagnosis that predicted shorter survival were greater number of body regions affected, lower forced vital capacity, and lower ALS Functional Rating Scale-Revised score. Noninvasive ventilation and gastrostomy were used frequently in PMA. CONCLUSION: Although patients with progressive muscular atrophy (PMA) tended to live longer than those with amyotrophic lateral sclerosis (ALS), shorter survival in PMA is associated with the same risk factors that predict poor survival in ALS. Additionally, PMA is relentlessly progressive, and UMN involvement can occur, as also reported in imaging and postmortem studies. For these reasons, PMA should be considered a form of ALS.

View Article
November 2009
22 Reads

Amyotrophic lateral sclerosis: clinical management and research update.

Authors:
Jinsy Andrews

Curr Neurol Neurosci Rep 2009 Jan;9(1):59-68

The Neurological Institute of New York, 710 West 168th Street, New York, NY 10032, USA.

View Article

Download full-text PDF

Source
January 2009
26 Reads
6 Citations
3.060 Impact Factor